

INFORMATION DISCLOSURE STATEMENT

ATTY.	DOCKET NUMBER MTH-0003-P2 SERIAL NUMBE	R 10/813,998 FILED 03/30/04					
		ALMIC PREPARATION					
CONT	AINING GLYCOMACROPEPTIDE EXAMINER	ART UNIT					
	EXAMINER	AKI UKII					
1. 🗖	Applicant submits herewith a copy of (a) attached form PTO-1449, which list submitted for consideration by the Office; (b) a legible copy of each document	sts all patents, publications, applications, or other information t required by 37 C.F.R. §1.98(b)(2).					
2. 🗖	Applicant herein apprises the Patent Office of references cited in a parent U.S. ap filing date under 35 U.S.C. §120. The Serial Number of the parent applicatio filed and entitled	n is U.S. Application					
	The publications cited therein are listed on attached Form PTO-1449. In accordance not required. Additional parent patent applications are listed on an attached patent applications.	rdance with 37 C.F.R. §1.98(d) copies of the listed publications tached sheet.					
3. 🗖	In accordance with 37 C.F.R. §1.98(a)(3), Applicant hereby certifies that for e A copy of a translation of one or more non-English document, or portion A concise explanation is (check at least one box below):	thereof, is provided herewith;					
	provided in the accompanying foreign or international search report;	incorporated into the specification; and/or provided herewith.					
	§1.97(b)(1), (b)(2) – WITHIN 3 MONTHS OF FILING OR ENTRY IN NATION						
4. 🗖	Since this Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an §1.97(e) is required.	of the filing date of the subject application of within three months international application, no fee or certification under 37 C.F.R.					
	s1.97(b)(3), (b)(4) – PRIOR TO MAILING OF FIRST OFFICE ACTION OR FIRST						
5. dz	Since this Information Disclosure Statement is being filed before the mailing of a first Office action after the filing of a request for continued examination §1.97(e) is required.						
37 C.F. R	. §1.97(c) – AFTER FIRST ACTION, BEFORE FINAL ACTION OR ALLOWA						
ô. 🚨	Since this Information Disclosure Statement is being filed outside of the perior of a Final Rejection or Notice of Allowance, this submission is being accompanied.	d provided for in 37 C.F.R. §1.97(b), but before the mailing date					
a. b.	the fee required under 37 C.F.R. §1.97(c)(2) and specified in 37 C.F.R. the statement specified in 37 C.F.R. §1.97(e) (Box 8 or 9 must be che	§1.17(p).					
37 C.F.R. 7. 🗀	§1.97(d) – AFTER FINAL REJECTION OR ALLOWANCE Since this Information Disclosure Statement is being filed after the period spec fee and is accompanied by both the statement specified in 37 C.F.R. §1.97(e	ified in 37 C.F.R. §1.97(c), but on or before payment of the issue					
	be checked.)						
8. 🗖	In accordance with 37 C.F.R. §1.97(e)(1), Applicant's attorney certifies that e Statement was first cited in any communication from a foreign patent office in a to the filling of this Information Disclosure Statement. The foreign or internation	counterpart foreign application not more than three months prior					
9. 🗖	In accordance with 37 C.F.R. §1.97(e)(2), Applicant's attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of the information disclosure statement.						
10. In the event the Commissioner of Patents deems that any additional fee is required under 37 C.F.R. §§ 1.16 or 1.17 in connection with this application, Applicant's attorneys authorize that such fee be charged to Deposit Account No. 06-1130.							
11. Consideration of this Information Disclosure Statement is respectfully requested.							
N	ame: Daniel F. Drexler	Registration Number 47,535					
Sign	ature On J2	Date 11-30-2005					
CERTIFICATE OF MAILING OR TRANSMISSION: I hereby certify that this correspondence is being deposited with the United States Postal Service with							
sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or [] facsimile transmitted to the Patent and Trademark Office to Facsimile No on the date shown below.							
N	Name Jennifer Lepage						
Sign	Signature Mundel Date 12-1-05						

•-	•-			Docket Number (Optional) MTH-0003-P2		Application Number 10/813,998			
	INFO	RMATION DISCLOSUR		_	Applicant(s)	D. TROU A.T.	10/013,55	<u> </u>	
		(Use several sheets if neces	sary) OIP	E	EDWARD J. ELLIS Filing Date		A		
			DECO	复	03/30/04		Group Art Unit		
 			PATE		TENT DOCUMENTS	<u>.</u>	****		
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	PARATE AND THE PROPERTY OF THE PARAMETER AND THE	STREET .	NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE
		5,578,586	11/26/96	Glonek	, et al.				
		5,371,108	12/06/94	Korb, e	et al.				
		5,294,607	03/15/94	Glonek	, et al.			_	· · · · · · · · · · · · · · · · · · ·
		5,278,151	01/11/94	Korb, et al. Glonek, et al. Guo					
		4,914,088	04/03/90						
		4,818,537	04/04/89						
	4,804,539		02/14/89	Guo, et al.					
		5,460,834	10/24/95	Bhagat					
	6,180,093 5,075,104		01/30/01	De, et al. Gressel, et al.					
			12/24/91						
		5,209,927	05/11/93	Gressel	, et al.				
				FOREIG	N PATENT DOCUMENT	S			
	REF	DOCUMENT NUMBER	DATE		COUNTRY CLASS		SUBCLASS	Translation	
								YES	NO
· 			<u> </u>	-	·				
			<u> </u>	<u> </u>				_	
					· · · · · · · · · · · · · · · · · · ·				
						ng Author, Title, D		-	
		Stuart Patton, et al.; " Acta 1241 (1995) page	The Epithelial M s 407-424	ucin, MUC	I, of Milk, Mammary G	land and Other	Tissue"; Bioche	emica et Bi	ophysica
		L.T. Pallesen, et al.; "! Full-Length cDNA Cle	Purification of Mone": J. Dairy Sci	UC1 from I . 84:2591-2	Bovine Milk-Fat Globule 598; American Diary Sc	es and Characte	rization of a Co	rrespondii	ıg
					,				
EXAMINER				DATE CONSIDERED					
		al if citation considered, whethe			Loce with MPEP Section 609	; Draw line throu	gh citation if not	in conform	ance and
not conside	red. In	clude copy of this form with nex	t communication to	applicant.					

Form PTO-A820

P09A/REV04

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE COATION (Use several sheets if necessary) OFC 05 2005 EDWARD J. ELLIS, ET AL. Filing Date 03/30/04 Group Art Unit O3/30/04 FILING DATE

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	
		5,225,196	07/06/93	Robinson	·			
		4,983,392	01/08/91	Robinson				
	_	4,615,697	10/07/86	Robinson				
		5,403,841	04/04/95	Lang, et al.				
		6,056,950	05/02/00	Saettone, et al.				
		4,438,100	03/20/84	Balslev, et al.				
		6,281,192	08/28/01	Leahy, et al.				
	-	6,429,194	08/06/02	Leahy, et al.				
	-	4,615,697	10/07/86	Robinson				
		5,188,826	02/23/93	Chandrasekaran, et al.				
		2002/0045582	04/18/02	Margolin, et al.				
		<u> </u>		FOREIGN PATENT DOCUMENTS		•		
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Trans	lation NO
								:
								-
						<u> </u>		<u></u>
	- 	International Search I	Report; PCT/US(OTHER DOCUMENTS (Including) 02/31657; 03 March 2003	g Author, Title, D	ite, Pertinent Pa	ges, Etc.)	
			• ,	,				
				Service Control of the Control of th				
								•

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	•	Docket Number (Optional)	Application Number			
The state of the s	ODM AMION DIGGLOGIDE OF ATION	MTH-0003-P2	10/813,998			
LNF	ORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) EDWARD J. ELLIS, ET AL.				
	,	Filing Date	Group Art Unit			
		03/30/04				
*EXAMINER	OTHER DOCUMENTS (Including Author, Title					
INITIAL	FUJIHARA et al., Lactoferrin suppresses loss of con Pharmacol Ther. April 1998; 14(2):99-107. Abstraction inherently autoclavable), in a concentration of 0.01 (i.e. dry eye treatment).	rneal epithelial integrity in a rabbit st t. Use of lactoferrin (glycoprotein iso to 1% as a suggested opthlamic prepa	ort-term dry eye model. J. Ocul latable from bovine milk whey, ration for corneal epithelial integrity			
	CHU et al. Isolation and characterization of porcin column, first paragraph (lactoferrin "molecular ma	ne milk lactoferrin. Am J Vet Res. July 1993; 54(7):1154-9 P. 1154, left lass is estimated to be between 72,000-85,000 daltons).				
	HWANGBO, et al. Purification and characterization antibody to PAS-4 glycoprotein in the bovine milk follows: 1568-74 P. 1571, left column, 4th paragraph, had 7.2%. P. 1568 discusses phospholipids and glycor together).	on of novel whey glycoprotein WGP-8 at globule membrane. Biosci Biotechi glycoproteins WGP-88 contained a 1 coproteins as constituents of bovine m	8 which binds to a monoclonal nol Biochem. September 1997; 7.1% carbohydrate and PAS-4 lk (which could be isolated alone			

EXAMINER		DATE CONSIDERED				
	nitial if citation considered, whether or not citation is in conformation in the conformation is in conformation.	nce with MPEP Section 609; Draw line th	ough citation if not in conformance and			

P09B/REV04